Published on 11 Nov 2017
Company summary: N4 Pharma Plc, formerly Onzima Ventures plc, is a UK-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B. Its vaccines include Nuvac and Nuvec.
The Company is improving Sildenafil for erectile dysfunction. Sartans is a family of drugs known as Angiotensin II antagonists, including Losartan and Valsartan, commonly used for the treatment of hypertension. Aprepitant is an anti-emetic drug used in oncology.
It is reformulating the existing Hepatitis B surface antigen vaccine (HBsAg), a sub unit vaccine. Nuvac is a nano-carrier delivery system for vaccines. Nuvec is an engineered silica nanoparticle, which has been designed for the intracellular delivery of large nucleic acids such as plasmid deoxyribonucleic acid and messenger ribonucleic acid.
This video presentation:
Introduction – 00:20
Business model – 01:19
The lead products: 1. Sidenafil MR (Viagra) – 02:13
Bringing it to market – 7:58
2. Nuvec (cancer treatment): Silica nanoparticles vaccine delivery system – 08:58
What are challenges and hooks for future marketing partners? – 23:49
Do you need regulatory approval? – 27:25
If you fund phase III yourselves, what royalty would you expect? – 28:01
Does the portfolio include any other products? – 28:55
Company Twitter account @n4pharma
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned